Details of the Drug Combinations

General Information of This Drug (ID: DM6OFJ8)

Drug Name

Indibulin DM6OFJ8

Synonyms

Indibulin; 204205-90-3; 2-(1-(4-chlorobenzyl)-1H-indol-3-yl)-2-oxo-N-(pyridin-4-yl)acetamide; d-24851; UNII-80K4H2RB8P; 80K4H2RB8P; ZIO-301; D 24851; 2-[1-(4-chlorobenzyl)-1h-indol-3-yl]-2-oxo-n-(pyridin-4-yl)acetamide; N-(Pyridin-4-yl)-[1-(4-chlorobenzyl)-indol-3-yl]-glyoxyl Amide; Indibulin [USAN:INN]; 2-{1-[(4-chlorophenyl)methyl]indol-3-yl}-2-oxo-N-(4-pyridyl)acetamide; 2-[1-[(4-chlorophenyl)methyl]indol-3-yl]-2-oxo-N-(4-pyridyl)acetamide; Indibulin (USAN/INN); AC1L1ESK; AC1Q5NS8; MLS006011745; CHEMBL49642

Indication

Disease Entry	ICD 11	Status	REF
Advanced sarcoma	2A60-2C35	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Indibulin + Capecitabine	DCCEASB	Capecitabine	Advanced Solid Tumors	[2]
Indibulin + Erlotinib	DCKV7I3	Erlotinib	Advanced Solid Tumors	[3]
------------------------------------------------------------------------------------

References

1	2011 Pipeline of ZioPharm.
2	ClinicalTrials.gov (NCT00726687) Phase 1b Study of Indibulin in Combination With Capecitabine in Advanced Solid Tumors
3	ClinicalTrials.gov (NCT00591383) Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors